New combo therapy aims to keep aggressive lung cancer at bay
NCT ID NCT07141264
Summary
This study is testing whether adding an oral chemotherapy pill (etoposide capsules) to an immunotherapy drug (adebrelimab) can help control extensive-stage small cell lung cancer after initial treatment. The trial will involve 32 patients in China whose cancer hasn't gotten worse after their first round of therapy. Researchers will track how long the cancer stays under control and monitor side effects of this maintenance treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital Affiliated to the Fourth Military Medical University
RECRUITINGXi'an, Shannxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.